வடமேற்கு பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Experts call new weight-loss drug groundbreaking and a game changer Steve Dorfman View Comments With some 70% of American adults being classified as either obese (42%) or overweight (28%), the battle to stem this epidemic received a new weapon earlier this month: FDA approval of semaglutide, an injectable drug made by the pharmaceutical company Novo Nordisk, for the use of weight-loss in those with a body-mass index (BMI) of 30 or more. In a statement announcing the approval, Dr. John Sharretts, deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research, said, “Today’s approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program. FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight.”

United statesRobertf kushnerJohn sharrettsVineeth mohanNorthwestern university school of medicineDivision of diabetesNorthwestern universityDepartment of endocrinologyNovo nordiskLipid disordersDrug evaluationNorthwestern university schoolCleveland clinic westonஒன்றுபட்டது மாநிலங்களில்திராட்சை மோகன்வடமேற்கு பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து